Text Size

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Lung Rx
ClinicalTrials.gov Identifier:
NCT00792571
First received: November 14, 2008
Last updated: April 16, 2013
Last verified: April 2013
History of Changes
  Purpose

This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.


Condition Intervention Phase
Pulmonary Arterial Hypertension
 Drug: Beraprost Sodium Modified Release
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Lung Rx:

Primary Outcome Measures:
  • The primary outcome is to assess the safety of long-term treatment with BPS-MR tablets in eligible patients who participated in BPS-MR-PAH-201 study [ Time Frame: In order to evaluate the long-term safety and efficacy of BPS-MR, the study is expected to continue until the first of either of the following is reached: December 31, 2014 or LungRx discontinues the project. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The secondary objectives are to describe the efficacy of BPS-MR tablets on an unencouraged 6-Minute Walk Test, the Borg Dyspnea Scale and Clinical Worsening in eligible patients who participated in the BPS-MR-PAH-201 study. [ Time Frame: In order to evaluate the long-term safety and efficacy of BPS-MR, the study is expected to continue until the first of either of the following is reached: December 31, 2014 or LungRx discontinues the project. ] [ Designated as safety issue: Yes ]

Enrollment: 18
Study Start Date: February 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: B.I.D
Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d
 Drug: Beraprost Sodium Modified Release
Comparison of different dosing frequency, BID vs QID
Other Names:
  • BPS-MR Tablets, 60 mcg
  • Beraprost Sodium Modified Release Tablet, 60 mcg
Experimental: Q.I.D
Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d
 Drug: Beraprost Sodium Modified Release
Comparison of different dosing frequency, BID vs QID
Other Names:
  • BPS-MR Tablets, 60 mcg
  • Beraprost Sodium Modified Release Tablet, 60 mcg

Detailed Description:

This is an open-label study for patients who participated in the BPS-MR-PAH-201 study and have volunteered to continue treatment for PAH with BPS-MR tablets. Each patient will return to the clinic following enrollment in the study at 3, 6, and 12 months, and annually thereafter for assessment.

Currently enrolled patients may be invited to participate in an optional four times daily (QID) dosing substudy of BPS-MR with total daily dose of BPS-MR achieved previously in the main study. Patients will return to the clinic for baseline visit, week 12, and then will follow the visit schedule provided to them in BPS-MR-PAH-202 main study.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who remained on study drug and completed all assessments during the Treatment Phase of Study BPS-MR-PAH-201 are eligible for this study.
  • Female patients must either be physiologically incapable of childbearing or be practicing an acceptable method of birth control (e.g. approved hormonal contraceptive, barrier method, such as condom or diaphragm, used with a spermicide, or an intrauterine device).

Exclusion Criteria:

  • Patients who discontinued study drug during the previous study (BPS-MR-PAH-201) for any reason (e.g. treatment related adverse events) are not eligible for entry into this study.
  • Patients who are pregnant or lactating are excluded from participation in the open-label extension.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00792571

Locations
United States, California
Harbor-UCLA Medical Center
Torrance, California, United States, 90502
United States, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, Texas
UTSW Medical Center Dallas
Dallas, Texas, United States, 75390-8550
Belgium
Universite Libre de Bruxelles
Bruxelles, Belgium
Gastuisberg University Hospital
Leuven, Belgium
Ireland
Mater Misericordiae University Hospital Ltd.
Dublin, Ireland
Sponsors and Collaborators
Lung Rx
Investigators
Study Director: Aimee Smart Study Sponsor
  More Information

No publications provided

Responsible Party: Lung Rx
ClinicalTrials.gov Identifier: NCT00792571     History of Changes
Other Study ID Numbers: BPS-MR-PAH-202
Study First Received: November 14, 2008
Last Updated: April 16, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypertension, Pulmonary
Hypertension
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Cardiovascular Diseases
Beraprost
Epoprostenol
 Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Vasodilator Agents
Cardiovascular Agents
Antihypertensive Agents

ClinicalTrials.gov processed this record on May 16, 2013